Pharmaceutical Market Europe • January 2021 • 42-44
APPOINTMENTS
Medicines Manufacturing Innovation Centre
MAUREEN WEDDERBURN
CPI has appointed Maureen Wedderburn chairperson of the Medicines Manufacturing Innovation Centre Supervisory Board. Wedderburn brings more than 35 years of industry knowledge and expertise to the role, primarily gained during her time at British pharma company GlaxoSmithKline (GSK). Her experience spans operational and technology remits, where she has led and strategically directed global product and transformational programmes across multinational businesses. Most recently, she served as senior vice president, pharma supply chain tech at GSK. Prior to this, she worked as senior vice president, global manufacturing and supply chain tech at GSK. Wedderburn also brings experience on supervisory boards to CPI – she currently serves as an advisory board member for CIONET UK, a community of IT executives who identify future trends and industry responses.
Gilead
JEFFREY BLUESTONE
Gilead Sciences has appointed Jeffrey Bluestone to the company’s board of directors. Currently, Bluestone serves as the president and chief executive officer of Sonoma Biotherapeutics, which is focused on developing regulatory T cell therapies. Recently, he also led the Parker Institute for Cancer Immunotherapy as president and chief executive officer. Bluestone is also the founding director of the Immune Tolerance Network.
CureVac
ANTONY BLANC
CureVac has appointed Antony Blanc as chief business officer and chief commercial officer. Blanc worked at GlaxoSmithKline between 2009-2017, where he held a number of senior roles at GSK Vaccines, including strategic marketing, strategic pricing and the integration of the Novartis Vaccines business unit. Prior to that, he held leadership roles at several biotech companies, including Synosia and Syngenta.
Novavax
RICK CROWLEY
Rick Crowley has been appointed as executive vice president, chief operations officer at Novavax. Prior to joining Novavax, Crowley was executive vice president, technical operations for TeSera Pharmaceuticals. He also served as senior vice president, operations and quality assurance at Crealta Pharmaceuticals. Previously, he held the role of co-president and chief operating officer at Savient Pharmaceuticals.
AB2 Bio
DJORDJE FILIPOVIC
AB2 Bio has has appointed Djordje Filipovic as chief commercial officer. Filipovic has more than 20 years of experience as a pharmaceutical executive, working across marketing, strategy and general management roles. Prior to joining AB2 Bio, he held a number of senior roles at Novartis, including overseeing the development and commercialisation of several key small molecules.
Sage Therapeutics
BARRY GREENE
Sage Therapeutics has appointed Barry Greene as chief executive officer. Most recently, Greene served as president of Alnylam Pharmaceuticals, where he held the role of chief operating officer. Prior to Alnylam, he was the general manager of oncology at Millennium Pharmaceutials, and earlier in his career he held multiple leadership positions at AstraZeneca.
Relief Therapeutics
CHRIS STIJNEN
Relief Therapeutics has appointed Chris Stijnen as chief commercial officer. Stijnen is an experienced pharmaceutical executive with a track record in a variety of roles, previously spending a significant time at Bristol Myers Squibb. Most recently, Stijnen served as vice president, product & portfolio strategy and interim head commercial strategy and capabilities for BMS in China.
NuCana
ANDREW KAY
NuCana has appointed Andrew Kay as chairman of its board of directors. Kay brings over 30 years of experience in building and leading biotech and pharma companies to NuCana. Currently, he serves as chairman of the board of NeRRe Therapeutics and Blueberry Therapeutics. He also recently held the same role at KaNDy Therapeutics, which was acquired by Bayer in 2020.
Transgene
HEDI BEN BRAHIM
Transgene has appointed Hedi Ben Brahim as chairman and chief executive officer. Ben Brahim has worked at Transgene since May 2019. Prior to Transgene, he served as vice president of immunotherapy at Institut Mérieux. In this role, he was the chairman of ABL, a contract research & development and contract biomanufacturing organisation.
Biofidelity
ROBERT OSBORNE
Robert Osborne has joined Biofidelity as chief operating officer. Osborne joins from Inivata, where he was senior vice president of technology and assay development. Previously, he worked as principal staff scientist at the Wellcome Trust Sanger Institute, director of technology development at 14M Genomics, and director of research at Population Genetic Technologies.
Congenica
BART WUURMAN
Congenica has appointed Muthu Meyyappan as chief commercial officer. Meyyappan has over 20 years' international experience working in genomics, clinical informatics and software companies. Prior to Congenica, he served as chief commercial officer at Variantyx where he held responsibility for the overall commercial strategy. Previously, he was also chief business officer for BIOBASE GmbH.
Engitix
EDUARDO BRAVO
Eduardo Bravo has joined Engitix as chairman of its board of directors. Bravo has over 25 years of senior management and board experience in the biopharmaceutical sector, having held the position of chief executive officer at Nordic Nanovector, TiGenix and Cellerix. Earlier in his career, he held several senior management positions at Sanofi-Aventis and SmithKline Beecham.
Enthera Pharmaceuticals
KAZUMI SHIOSAKI
Enthera Pharmaceuticals, based in Milan, Italy, has appointed Kazumi Shiosaki to its board of directors. Currently, Shiosaki serves as the chief executive officer of Twentyeight-Seven, a biotech company focused on novel RNA biology. She was also a co-founder and chief executive officer of Mitobridge and previously also the CEO of Epizyme.
Enthera Pharmaceuticals
LISA OLSON
Also joining Enthera Pharmaceuticals is Lisa Olson, who joins the company’s scientific advisory board. Olson is a senior pharmaceutical executive with over 20 years of experience in research and drug discovery. She is currently chief scientific officer and head of research at Magenta Therapeutics. Prior to joining Magenta, Olson spent 15 years in leadership positions at AbbVie Bioresearch Center.
NanoSyrinx
JANE DANCER
NanoSyrinx has appointed Jane Dancer to its board of directors as non-executive director. Dancer has over 30 years of experience in business development across biotech, pharma and agrochemicals, with previous roles including chief business officer at F-star. She also held the role of vice president of business development at Cellzome and director, business development at MedImmune.
Nouscom
GÖRAN ANDO
Nouscom, based in Basel, Switzerland, has appointed Göran Ando as its new chairman of the board of directors. Ando has over 35 years of leadership and management experience in the biotech and pharmaceutical industry. He sits on the boards of several global companies, including Eyepoint Pharma. He began his career at Pfizer, where he held several senior clinical positions in Europe and the US.
Nouscom
RICHARD DAVIS
Nouscom has also welcomed Richard Davis as its chief business officer. Davis is an accomplished executive with more than 20 years of experience in the life sciences sector. Prior to joining Nouscom, he served as global oncology transactor at Johnson & Johnson Innovation. Previously, he also held executive roles in both private and public European biotech companies.
Enara Bio
ERIK RUTJENS
Enara Bio has appointed Erik Rutjens as vice president, cell therapy operations. Rutjens joins from Novartis, where he was head of enabling technologies and process engineering. At Novartis, he played a key role in the development of the Swiss pharma company’s T-cell therapy Kymriah. Prior to Novartis, he held various positions at PharmaCell (now Lonza).
Enara Bio
SADIK KASSIM
Enara Bio has also appointed Sadik Kassim to its scientific advisory board. Kassim is currently chief technology officer at Vor Biopharma. Prior to this, he served as executive director at Kite Pharma and chief scientific officer at Mustang Bio. Kassim was also head of early analytical development at Novartis’ cell and gene therapies unit.
Enara Bio
MICHAEL QUIGLEY
Rounding out the appointments at Enara Bio is Michael Quigley, who joins the scientific advisory board. Currently, Quigley serves as a senior vice president leading Gilead’s Research Biology Group. Previously, he was also vice president and head of the Tumour Microenvironment Modulation Center at Bristol Myers Squibb. He also previously held positions at Janssen and MedImmune.
Touchlight
SATISH MUCHAKAYALA
Touchlight has appointed Satish Muchakayala as director of regulatory affairs. Muchakayala has over 14 years' global regulatory experience in the pharma industry. Prior to Touchlight, he worked in various regulatory positions at UCB, Johnson & Johnson and GlaxoSmithKline. He has a Master’s degree in Pharmaceutical Sciences and is a consultant editor for TOPRA Regulatory Rapporteur.
McCann Health
SANDRA CAREY
McCann Health has promoted Sandra Carey to the new role of global president, expert audiences. Prior to her promotion, Carey served as global president, McCann Health pharmacy market. Prior to joining McCann, Carey held leadership positions in retail, international and national regulatory bodies. She has also been a practising pharmacist and practitioner for most of her career.
Publicis Health
KARA DUGAN
Publicis Health has appointed Kara Dugan as president of Razorfish Health. Dugan has spent more than a decade at Publicis Group, working across a variety of roles with increasing responsibilities. She has successfully led key global accounts in healthcare, and most recently served as general manager of the Razorfish agency. Before joining Publicis, she worked at GlaxoSmithKline as global communications director.
Nucleus Global
DAN BRIDGES
Nucleus Global has appointed Dan Bridges as its new chief executive officer. Bridges brings over 15 years’ experience in medical communications to the role. Most recently, he served as Nucleus Global’s regional director, Europe, a role in which he led eight agencies. Bridges also brings to the role extensive therapeutic expertise, industry knowledge and strategic business partnering experience.
Nucleus Global
REENA MAMMAN
Nucleus Global has also promoted Reena Mamman to the role of chief operating officer and chief financial officer. Mamman joined Nucleus Global 12 years ago as European finance director. In her new role, she will focus on maintaining the finance function of Nucleus Global while supporting the company’s continued growth and development.
Nucleus Global
VICKY MALHERBE
Rounding out the senior leadership promotions at Nucleus Global is Vicky Malherbe, who takes on the role of group chief financial officer. Malherbe joined Nucleus Global in 2010, and prior to this new promotion she headed up the company’s financial group in the US. Alongside Mamman, she will help to support the continued development of Nucleus Global.
Synergy Vision
EILEEN GALLAGHER
Synergy Vision has appointed Eileen Gallagher to the role of chief operating officer. Gallagher has worked at Synergy Vision since its inception, having been part of the founding team. During her time at Synergy, she has worked as both a director and managing director. Prior to this, she worked at GlaxoSmithKline for a period of 11 years in a number of roles.
Synergy Vision
KARINE HENDERSON
Also joining the executive team at Synergy Vision is Karine Henderson, who will take on the role of managing director. Before taking on the managing director position, Henderson worked as director of medical strategy at Synergy, having joined just over one year ago. She has over 20 years of healthcare communication experience, across both the client and agency settings.
Evoke KYNE
SARAH COOPER WELTY
Health communications agency Evoke KYNE has promoted Sarah Cooper Welty to senior vice president. Cooper Welty has worked at Evoke KYNE since 2013 – prior to this, she worked as a consultant. During her time working as a consultant, she provided communications and event planning support to a lifestyle public relations agency based in the US.
Evoke KYNE
LAUREN ELLERT
Evoke KYNE has also promoted Lauren Ellert to the role of vice president. Ellert joined Evoke KYNE in 2016, after working for six years in the publicity departments at HarperCollins and Random House. At Evoke KYNE, she has led a variety of communications initiatives across therapeutic areas, including patient advocacy relations, launches and product approvals.
Evoke KYNE
KAREN URBAN
Rounding out the appointments at Evoke KYNE is Karen Urban, who has also joined as a vice president. Urban brings more than a decade of health-focused public relations experience to Evoke KYNE. She specialises in awareness campaigns and special events, having worked with high-profile physicians, celebration and influencers on behalf of major pharma companies.
Research Partnership
HANNAH OSBORN
Research Partnership has appointed Hannah Osborn as a MedTech director in its London, UK office. Osborn has over 13 years’ experience in healthcare research and consulting, with a focus on medical devices over the past seven years. Previously, she worked for Ipsos as director for its MedTech Asia-Pacific (APAC) team, and for IQVIA as an engagement manager.
Page & Page and Partners
GEORGIE EPPS
AND KIRSTIE TURNER
Georgie Epps has joined Page & Page and Partners as a mid-weight graphic designer. Epps has four years of experience with a background working in agency and in-house design. Also joining Page & Page and Partners is Kirstie Turner, who has been appointed as a writer and editor. Turner joins from EMJ, where she worked as a content manager.